Effects of Jive Dance Training on Lower Limb Muscle Strength

June 6, 2026 updated by: HSU YU LING, E-DA Hospital

The Health-promoting Effects of Ballroom Dancing Courses on Lower Limb Strength, Dynamic Balance, Body Composition, and Working Memory of Hospital Employees

The purpose of this study is to evaluate the effects of a structured, partner-free Jive dance training program on the physical and cognitive health of hospital employees. Healthcare workers often face high-stress environments, irregular shifts, and prolonged physical strain, which can lead to reduced muscle strength, poor body composition, and burnout. This study innovates by designing a solo Jive dance intervention to overcome traditional partnership limitations in workplace wellness programs.

A single-group repeated measures design was used, recruiting 20 hospital employees for an 8-week study. The study was divided into Phase A (4 weeks of self-directed group practice) and Phase B (4 weeks of systematic Jive dance training). Comprehensive assessments were conducted at baseline, week 4, and week 8 to measure body composition, lower limb muscle strength, dynamic balance, working memory, and perceived stress.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Active, not recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
20

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Taiwan
    • Taiwan
      • Kaohsiung, Taiwan, Taiwan, 824
        • E-Da Cancer Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Currently employed as a full-time or part-time staff member at the hospital.
  • Aged between 18 and 65 years.
  • Voluntarily willing to participate in the 8-week dance program and complete all sequential phases (Phase A and Phase B).
  • Mentally and physically capable of performing moderate-to-high intensity structured exercise (such as solo Jive dancing).
  • Able to understand the study protocols and provide written informed consent.

Exclusion Criteria:

  • Pre-existing severe musculoskeletal injuries, severe joint degeneration, or acute pain that restricts dancing or weight-shifting movements.
  • Uncontrolled cardiovascular diseases (e.g., severe hypertension, arrhythmia, or unstable angina) that render high-intensity aerobic exercise unsafe.
  • Current pregnancy or plans to become pregnant during the 8-week intervention period.
  • Undergoing regular professional or competitive athletic training that could introduce significant confounding effects to the physical outcomes.
  • Any other medical condition, severe cognitive impairment, or physical limitation judged by the investigator to pose a safety risk during exercise or interfere with data collection.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Solo Jive Dance Training Group
All participants in this single group will sequentially undergo two distinct phases over an 8-week period. Phase A involves 4 weeks of self-directed group practice, which serves as the comparison stage. This is immediately followed by Phase B, consisting of 4 weeks of a systematic, structured solo Jive dance training program (60 minutes per session) designed to enhance physical and cognitive functions.
Behavioral: Systematic Solo Jive Dance Training

This intervention features an innovative, partner-free "Solo Jive" ballroom dance curriculum designed to overcome the barrier of partner limitations in traditional workplace wellness programs. Distinct from general dance activities, this program is structured into two sequential 4-week phases: a self-directed group practice phase followed by a highly systematic, supervised professional training phase.

The core curriculum emphasizes continuous rhythmic tracking, agility, and fast-paced weight-shifting movements characteristic of Jive, focusing heavily on bilateral lower-limb coordination. It is tailored to address healthcare workers' occupational strains, integrating physical neuromuscular training with cognitive-motor engagement (working memory) to provide a dual-benefit intervention for adult workplace populations.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Change in Bilateral Lower Limb Plantar Flexion Muscle Strength
Time Frame: Baseline (T0), Week 4 (T4), and Week 8 (T8)
Lower limb muscle strength (specifically plantar flexion) is measured to evaluate the neuromuscular effects of the systematic Jive dance training. Measurements are taken using a digital handheld dynamometer. The recorded values are expressed in pounds (lbs) to capture quantitative changes. An increase in the measured force values from baseline indicates an improvement in lower limb muscle strength.
Baseline (T0), Week 4 (T4), and Week 8 (T8)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
E-DA Hospital

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: YU LING HSU, Clinical Dietitian, E-Da Cancer Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
October 21, 2025

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
December 12, 2025

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
July 31, 2026

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
June 1, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
June 6, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
June 11, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
June 11, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
June 6, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
June 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • EMRP-114-068

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

To protect participant privacy and comply with institutional data protection regulations, individual participant data will not be publicly shared. The findings will be available through aggregated statistical summaries in subsequent research reports.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings